NCT06794125Recruiting
An Evaluation of Dose-escalation for Intrathoracic Tumours
A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 141 (estimated)
- First submitted
- 21 Jan 2025
- Start date
- 3 Sept 2025
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Chris Goodman
- Diseases
- Lung cancer
- NCT number
- NCT06794125
What you commit to
- Study type: Interventional
- Planned participants: 141
- From 3 Sept 2025 to the primary completion date, 1 Mar 2029
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT plans must be created, and the dose constraints herein must still be met. An allowance for 10 percent repair is permitted if at least 12 months have passed between the prior radiotherapy and the trial protocol specified radiotherapy.
- Inability to attend the full course of radiotherapy or planned follow-up visits
Other illness
- Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease.
Other
- Pregnant or lactating women
Who the study is looking for
- Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator)
- Willingness and ability to provide informed consent
- Eastern Cooperative Oncology Group performance status 0-3
- Age 18 years or older
- Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist
- Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist.
- Life expectancy greater than 3 months
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Recruiting |
| London Health Sciences Center Research Institute (Formerly Lawson Research Institute) Coordinator of this site? Confirm its status | London | Canada | Recruiting |
| Horizon Health New Brunswick Coordinator of this site? Confirm its status | Saint John | Canada | Recruiting |
| Waterloo Regional Health Network Coordinator of this site? Confirm its status | Waterloo | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.